Boston Scientific (NYSE:BSX) Stock Crosses Below Fifty Day Moving Average – Here’s Why

Boston Scientific Corporation (NYSE:BSX)’s stock price crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $45.29 and traded as low as $44.86. Boston Scientific shares last traded at $44.9480, with a volume of 15,120,965 shares.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
• Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
• Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
• Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
• Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Mizuho set a $50.00 target price on Boston Scientific in a research note on Thursday. Oppenheimer lowered shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday. Wells Fargo & Company reduced their price target on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research report on Thursday. The Goldman Sachs Group dropped their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.87.

Boston Scientific Stock Performance

The stock has a market cap of $61.86 billion, a PE ratio of 13.30, a PEG ratio of 1.04 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a 50 day moving average of $44.93 and a two-hundred day moving average of $57.15.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.07 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company’s revenue was up 1.4% on a year-over-year basis. During the same period last year, the firm posted $0.75 EPS. Research analysts predict that Boston Scientific Corporation will post 3.18 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director David C. Habiger acquired 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Boston Scientific in the 2nd quarter worth about $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific during the 2nd quarter valued at $2,156,233,000. Janus Henderson Group PLC grew its position in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Amundi increased its stake in Boston Scientific by 13.8% in the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after purchasing an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after purchasing an additional 2,856,040 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.